Credit: PROFESSOR JOHN ZAJICEK/Science Source
And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.
The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.
Walk with us.
Gray-matter atrophy was found in almost all the brain networks of patients with multiple sclerosis (MS), yet varies across phenotypes, a multicenter European study has confirmed, with atrophy in certain areas predicting disability and clinical worsening.
Researchers have developed a new classification of cognitive function for patients with multiple sclerosis (MS) that is based on the identification of five cognitive phenotypes.
Researchers have found that administering a drug for multiple sclerosis (MS) significantly improves cognitive processing speed in patients who have secondary progressive MS compared with placebo, according to a new study.
As Gavin Giovannoni, MBBCh, PhD, an esteemed British multiple sclerosis (MS) expert, set out for his Saturday morning run on Nov. 7, 2020, the world’s weighty problems swirled through his head. Brexit, a U.S. election, a global pandemic, not to mention the daily struggles of his patients with their degenerative illness.
The distinct way immune cells respond to viruses like Epstein-Barr in people with the HLA-DR15 gene variant plays a significant role in the development of multiple sclerosis (MS), according to new research into what causes the autoimmune disease.